SrasV1, PascalFrancis, Curation, bibRecord, 000307

Current status of anti-SARS agents

Identifieur interne : 000307 ( PascalFrancis/Curation ); précédent : 000306; suivant : 000308

Current status of anti-SARS agents

Auteurs : Shiro Shigeta [Japon] ; Toshihiro Yamase [Japon]

Source :

Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2005.

RBID : Pascal:05-0234428

Descripteurs français

Pascal (Inist)
- Relation structure activité, Syndrome respiratoire aigu sévère, Coronavirus, Antiviral, Article synthèse, Réplication.

English descriptors

KwdEn :
- Antiviral, Coronavirus, Replication, Review, Severe acute respiratory syndrome, Structure activity relation.

Abstract

Severe acute respiratory syndrome (SARS) is a disease that has newly emerged in the 21st century, and is both severe and highly contagious. SARS first surfaced in late 2002 and spread within a few months from its origin in Guandong province, China, to more than 30 countries (World Health Organization, 2003). In this review, several antiviral substances shown to be active in vitro will be introduced and summarized in the order of the virus' replication steps; that is, binding to cellular receptor, fusion and entry to the cells, viral RNA replication and transcription, protein processing and so on. The possible clinical use of several synthetic peptides, including those that mimic the S-binding domain, the HR2 fusion protein and SARS proteinase substrates, will be discussed. Monoclonal antibodies (Mabs) and established drugs, such as interferons and HIV proteinase inhibitors, are also discussed in relation to anti-SARS clinical use.

A01	`01`	`1`		`@0 0956-3202`
A03		`1`		`@0 Antivir. chem. chemother.`
A05				`@2 16`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Current status of anti-SARS agents`
A11	`01`	`1`		`@1 SHIGETA (Shiro)`
A11	`02`	`1`		`@1 YAMASE (Toshihiro)`
A14	`01`			`@1 Department of Microbiology, Fukushima Medical University, School of Medicine @2 Fukushima @3 JPN @Z 1 aut.`
A14	`02`			`@1 Research Laboratory of Resources Utilization, Tokyo Institute of Technology @2 Midori-ku, Yokohama @3 JPN @Z 2 aut.`
A20				`@1 23-31`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22101 @5 354000121167610030`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 05-0234428`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral chemistry & chemotherapy`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Severe acute respiratory syndrome (SARS) is a disease that has newly emerged in the 21st century, and is both severe and highly contagious. SARS first surfaced in late 2002 and spread within a few months from its origin in Guandong province, China, to more than 30 countries (World Health Organization, 2003). In this review, several antiviral substances shown to be active in vitro will be introduced and summarized in the order of the virus' replication steps; that is, binding to cellular receptor, fusion and entry to the cells, viral RNA replication and transcription, protein processing and so on. The possible clinical use of several synthetic peptides, including those that mimic the S-binding domain, the HR2 fusion protein and SARS proteinase substrates, will be discussed. Monoclonal antibodies (Mabs) and established drugs, such as interferons and HIV proteinase inhibitors, are also discussed in relation to anti-SARS clinical use.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Relation structure activité @5 11`
C03	`01`	`X`	`ENG`	`@0 Structure activity relation @5 11`
C03	`01`	`X`	`SPA`	`@0 Relación estructura actividad @5 11`
C03	`02`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 12`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 12`
C03	`02`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 12`
C03	`03`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 14`
C03	`03`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 14`
C03	`03`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 14`
C03	`04`	`X`	`FRE`	`@0 Antiviral @5 15`
C03	`04`	`X`	`ENG`	`@0 Antiviral @5 15`
C03	`04`	`X`	`SPA`	`@0 Antiviral @5 15`
C03	`05`	`X`	`FRE`	`@0 Article synthèse @5 16`
C03	`05`	`X`	`ENG`	`@0 Review @5 16`
C03	`05`	`X`	`SPA`	`@0 Artículo síntesis @5 16`
C03	`06`	`X`	`FRE`	`@0 Réplication @5 17`
C03	`06`	`X`	`ENG`	`@0 Replication @5 17`
C03	`06`	`X`	`SPA`	`@0 Replicación @5 17`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 61`
C07	`06`	`X`	`ENG`	`@0 Respiratory disease @5 61`
C07	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 61`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 62`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 62`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 62`
N21				`@1 157`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000683

Links to Exploration step

Pascal:05-0234428

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Current status of anti-SARS agents</title>
<author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Fukushima Medical University, School of Medicine</s1>
<s2>Fukushima</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Research Laboratory of Resources Utilization, Tokyo Institute of Technology</s1>
<s2>Midori-ku, Yokohama</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0234428</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0234428 INIST</idno>
<idno type="RBID">Pascal:05-0234428</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000683</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000307</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Current status of anti-SARS agents</title>
<author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Fukushima Medical University, School of Medicine</s1>
<s2>Fukushima</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Research Laboratory of Resources Utilization, Tokyo Institute of Technology</s1>
<s2>Midori-ku, Yokohama</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral chemistry & chemotherapy</title>
<title level="j" type="abbreviated">Antivir. chem. chemother.</title>
<idno type="ISSN">0956-3202</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Coronavirus</term>
<term>Replication</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Structure activity relation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Antiviral</term>
<term>Article synthèse</term>
<term>Réplication</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a disease that has newly emerged in the 21st century, and is both severe and highly contagious. SARS first surfaced in late 2002 and spread within a few months from its origin in Guandong province, China, to more than 30 countries (World Health Organization, 2003). In this review, several antiviral substances shown to be active in vitro will be introduced and summarized in the order of the virus' replication steps; that is, binding to cellular receptor, fusion and entry to the cells, viral RNA replication and transcription, protein processing and so on. The possible clinical use of several synthetic peptides, including those that mimic the S-binding domain, the HR2 fusion protein and SARS proteinase substrates, will be discussed. Monoclonal antibodies (Mabs) and established drugs, such as interferons and HIV proteinase inhibitors, are also discussed in relation to anti-SARS clinical use.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0956-3202</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. chem. chemother.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Current status of anti-SARS agents</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SHIGETA (Shiro)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YAMASE (Toshihiro)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Microbiology, Fukushima Medical University, School of Medicine</s1>
<s2>Fukushima</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Research Laboratory of Resources Utilization, Tokyo Institute of Technology</s1>
<s2>Midori-ku, Yokohama</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>23-31</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22101</s2>
<s5>354000121167610030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0234428</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral chemistry & chemotherapy</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is a disease that has newly emerged in the 21st century, and is both severe and highly contagious. SARS first surfaced in late 2002 and spread within a few months from its origin in Guandong province, China, to more than 30 countries (World Health Organization, 2003). In this review, several antiviral substances shown to be active in vitro will be introduced and summarized in the order of the virus' replication steps; that is, binding to cellular receptor, fusion and entry to the cells, viral RNA replication and transcription, protein processing and so on. The possible clinical use of several synthetic peptides, including those that mimic the S-binding domain, the HR2 fusion protein and SARS proteinase substrates, will be discussed. Monoclonal antibodies (Mabs) and established drugs, such as interferons and HIV proteinase inhibitors, are also discussed in relation to anti-SARS clinical use.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>15</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Review</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Réplication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Replication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Replicación</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>62</s5>
</fC07>
<fN21><s1>157</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000307 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000307 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0234428
   |texte=   Current status of anti-SARS agents
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Current status of anti-SARS agents

Current status of anti-SARS agents

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri